Literature DB >> 3951020

Interaction of West Nile virus with primary murine macrophages: role of cell activation and receptors for antibody and complement.

M J Cardosa, S Gordon, S Hirsch, T A Springer, J S Porterfield.   

Abstract

We have measured growth of West Nile virus in mouse primary peritoneal macrophages (resident, thioglycolate elicited, and Mycobacterium bovis BCG activated) and in macrophagelike (P338D1) and nonmacrophage (L929, PS clone D) cell lines infected in the absence or presence of specific antibodies (immunoglobulin G ([IgG], IgM), and complement. Monoclonal antibodies directed against Fc receptors (IgG1/2b, 2.4G2) and type 3 complement receptors (Mac-1) were used to define the role of each receptor. Virus yield depended on a balance between enhancement and neutralization and was influenced by the physiologic state of the macrophage, the receptor pathway of viral entry, the mouse strain and age of donor. BCG-activated macrophages displayed a greater ability to restrict West Nile virus than nonactivated cells only in the presence of antiviral IgM, with or without complement; the Fc receptors for various classes of IgG mediated striking enhancement. These studies identify some of the complex innate and acquired factors that determine the interaction between West Nile virus and primary macrophages in vitro.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3951020      PMCID: PMC252826     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  31 in total

1.  Genetic factors affecting susceptibility and resistance to virus diseases of the nervous system.

Authors:  A B SABIN
Journal:  Res Publ Assoc Res Nerv Ment Dis       Date:  1954

Review 2.  Structural Aspects and Heterogeneity of Immunoglobulin Fc Receptors.

Authors:  J C Unkeless; H Fleit; I S Mellman
Journal:  Adv Immunol       Date:  1981       Impact factor: 3.543

3.  Monoclonal anti-Fc receptor IgG blocks antibody enhancement of viral replication in macrophages.

Authors:  J S Peiris; S Gordon; J C Unkeless; J S Porterfield
Journal:  Nature       Date:  1981-01-15       Impact factor: 49.962

4.  Complement receptor mediates enhanced flavivirus replication in macrophages.

Authors:  M J Cardosa; J S Porterfield; S Gordon
Journal:  J Exp Med       Date:  1983-07-01       Impact factor: 14.307

5.  Augmentation of macrophage complement receptor function in vitro. III. C3b receptors that promote phagocytosis migrate within the plane of the macrophage plasma membrane.

Authors:  F M Griffin; P J Mullinax
Journal:  J Exp Med       Date:  1981-08-01       Impact factor: 14.307

6.  Studies of the macrophage complement receptor. Alteration of receptor function upon macrophage activation.

Authors:  C Bianco; F M Griffin; S C Silverstein
Journal:  J Exp Med       Date:  1975-06-01       Impact factor: 14.307

7.  Role of activated macrophages in antibody-dependent lysis of tumor cells.

Authors:  C Nathan; L Brukner; G Kaplan; J Unkeless; Z Cohn
Journal:  J Exp Med       Date:  1980-07-01       Impact factor: 14.307

8.  A human leukocyte differentiation antigen family with distinct alpha-subunits and a common beta-subunit: the lymphocyte function-associated antigen (LFA-1), the C3bi complement receptor (OKM1/Mac-1), and the p150,95 molecule.

Authors:  F Sanchez-Madrid; J A Nagy; E Robbins; P Simon; T A Springer
Journal:  J Exp Med       Date:  1983-12-01       Impact factor: 14.307

9.  Surface properties of bacillus Calmette-Guérin-activated mouse macrophages. Reduced expression of mannose-specific endocytosis, Fc receptors, and antigen F4/80 accompanies induction of Ia.

Authors:  R A Ezekowitz; J Austyn; P D Stahl; S Gordon
Journal:  J Exp Med       Date:  1981-07-01       Impact factor: 14.307

10.  Identification of interferon-gamma as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity.

Authors:  C F Nathan; H W Murray; M E Wiebe; B Y Rubin
Journal:  J Exp Med       Date:  1983-09-01       Impact factor: 14.307

View more
  25 in total

1.  Complement protein C1q inhibits antibody-dependent enhancement of flavivirus infection in an IgG subclass-specific manner.

Authors:  Erin Mehlhop; Camilo Ansarah-Sobrinho; Syd Johnson; Michael Engle; Daved H Fremont; Theodore C Pierson; Michael S Diamond
Journal:  Cell Host Microbe       Date:  2007-12-13       Impact factor: 21.023

2.  Isolation and characterization of human monoclonal antibodies from individuals infected with West Nile Virus.

Authors:  Mark Throsby; Cecile Geuijen; Jaap Goudsmit; Arjen Q Bakker; Jehanara Korimbocus; R Arjen Kramer; Marieke Clijsters-van der Horst; Maureen de Jong; Mandy Jongeneelen; Sandra Thijsse; Renate Smit; Therese J Visser; Nora Bijl; Wilfred E Marissen; Mark Loeb; David J Kelvin; Wolfgang Preiser; Jan ter Meulen; John de Kruif
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

3.  Differential responses of human brain cells to West Nile virus infection.

Authors:  Maxim C-J Cheeran; Shuxian Hu; Wen S Sheng; Ayesha Rashid; Phillip K Peterson; James R Lokensgard
Journal:  J Neurovirol       Date:  2005-12       Impact factor: 2.643

4.  Complement activation is required for induction of a protective antibody response against West Nile virus infection.

Authors:  Erin Mehlhop; Kevin Whitby; Theodore Oliphant; Anantha Marri; Michael Engle; Michael S Diamond
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

5.  West Nile virus surveillance and diagnostics: A Canadian perspective.

Authors:  Michael A Drebot; Robbin Lindsay; Ian K Barker; Peter A Buck; Margaret Fearon; Fiona Hunter; Paul Sockett; Harvey Artsob
Journal:  Can J Infect Dis       Date:  2003-03

6.  B cells and antibody play critical roles in the immediate defense of disseminated infection by West Nile encephalitis virus.

Authors:  Michael S Diamond; Bimmi Shrestha; Anantha Marri; Darby Mahan; Michael Engle
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

Review 7.  Progress on the development of therapeutics against West Nile virus.

Authors:  Michael S Diamond
Journal:  Antiviral Res       Date:  2009-06-06       Impact factor: 5.970

8.  Antibody prophylaxis and therapy against West Nile virus infection in wild-type and immunodeficient mice.

Authors:  Michael J Engle; Michael S Diamond
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

9.  Infection and injury of neurons by West Nile encephalitis virus.

Authors:  Bimmi Shrestha; David Gottlieb; Michael S Diamond
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

Review 10.  Complement and its role in protection and pathogenesis of flavivirus infections.

Authors:  Panisadee Avirutnan; Erin Mehlhop; Michael S Diamond
Journal:  Vaccine       Date:  2008-12-30       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.